Fundraising Fox

Sarepta Therapeutics

Cambridge, US · 2 known investors

sarepta.com ↗

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

BiotechHealthtech

Founders & leadership

WC
WILLIAM CIAMBRONEExecutive
DS
DOUGLAS S. INGRAMExecutive
DT
DAVID TYRONNE HOWTONExecutive
SM
SANDESH MAHATMEExecutive
GO
GILMORE O'NEILLExecutive
AC
ALEXANDER CUMBOExecutive
RJ
RICHARD J. BARRYNamed on SEC filing
MW
MICHAEL W. BONNEYNamed on SEC filing

Board

HW
HANS WIGZELLBoard director
CN
CLAUDE NICAISEBoard director
MA
MARY ANN GRAYBoard director
MK
M. KATHLEEN BEHRENSBoard director

Investors · 2

Avoro Capital AdvisorsNew York
Roche Venture FundBasel · $648K – $3.2M

Reported raises · per SEC filings

Form D private placements

$430.5M disclosed across 2 rounds · 2019–2020

▶$400MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL W. BONNEYDirector
  • MARY ANN GRAYDirector
  • CLAUDE NICAISEDirector
  • HANS WIGZELLDirector
  • JOHN C. MARTINDirector
  • DOUGLAS S. INGRAMExecutive Officer, Director
  • ALEXANDER CUMBOExecutive Officer
  • DAVID TYRONNE HOWTONExecutive Officer
  • SANDESH MAHATMEExecutive Officer
  • GILMORE O'NEILLExecutive Officer
  • WILLIAM CIAMBRONEExecutive Officer
  • M. KATHLEEN BEHRENSDirector
  • RICHARD J. BARRYDirector
Offering amount
$400M
Amount sold
$400M
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.5MraisedNov 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM CIAMBRONEExecutive Officer
  • HANS WIGZELLDirector
  • CLAUDE NICAISEDirector
  • DOUGLAS S. INGRAMExecutive Officer, Director
  • DAVID TYRONNE HOWTONExecutive Officer
  • MARY ANN GRAYDirector
  • SANDESH MAHATMEExecutive Officer
  • GILMORE O'NEILLExecutive Officer
  • M. KATHLEEN BEHRENSDirector
  • RICHARD J. BARRYDirector
  • MICHAEL W. BONNEYDirector
  • ALEXANDER CUMBOExecutive Officer
Offering amount
$30.5M
Amount sold
$30.5M
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Seeking Alpha140 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.

Companies competing with Sarepta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap?finance.yahoo.com · Aug 2026

Frequently asked questions

What does Sarepta Therapeutics do?
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Who are Sarepta Therapeutics's investors?
Sarepta Therapeutics's investors include Avoro Capital Advisors, Roche Venture Fund.
How much funding has Sarepta Therapeutics raised?
Sarepta Therapeutics has disclosed $430.5M raised across 2 rounds.
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics is headquartered in Cambridge, US.